简介：

简介：

简介：Hearinglossisoneofthemostfrequenthealthissuesinindustrializedcountries.Thepathogenesisandmolecularmechanismsofhearinglossarestillunclear.Histonedeacetylases(HDACs)areemergingaskeyenzymesinmanyphysiologicalprocesses,includingchromatinremodeling,regulationoftranscription,DNArepair,metabolism,genomestabilityandproteinsecretion.RecentstudiesindicatedthatHDACsareassociatedwiththedevelopmentandprogressionofhearingloss.DysfunctionofHDACscouldpromotetheoxidativestressandagingintheinnerear.Inlightofconsideringthecurrentstagnationinthedevelopmentoftherapeuticoptions,theneedfornewstrategiesinthetreatmentofhearinglosshasneverbeensopressing.Inthisreview,wewillsummarizethereportedliteraturesforHDACsinhearinglossanddiscusshowHDACfamilymembersshowdifferentperformancesforthepossibilityofprocessofdiseasesdevelopment.Thepossibilityofpharmacologicalinterventiononhearinglossopensanovelpathinthetreatmentofhearingloss.

简介：

简介：Despiterecentprogressinourunderstandingofcancerbiologyandinmanyareasofcancertreatment,thesuccessrateforcancertherapyremainsdismal.Immunotherapyforcancerhaslongbeenanexcitingfieldformanycancerresearchersduetothepossibilitytomobilizethebody'sownimmunesystemtoeradicatecancernotonlylocallybutalsosystemically.Sinceitsinitialdiscovery,cytokine-basedimmunotherapyhasbeenvigorouslyandextensivelyinvestigatedforcancertreatmentduetotheperceptionofitasarelativelyeasilypurifiable,injectableformofcancertreatmentagent.However,sofarmostcytokine-basedtherapytrialshavefallenshortofexpectations.Oneofmainobstaclesisthedifficultytoachievetherapeuticallyrelevantdosageinpatientswithoutgeneratingexcessivenormaltissuetoxicity.Theemergenceofnovelgenetherapyapproachtodelivertherapeuticcytokinetotumorslocallygeneratedgreatexcitementsinceithasthepotentialofgeneratingsustainedhighlocalconcentrationofimmunostimulatorycytokinewithoutraisingthesystemiclevelsofthecytokines,whichisresponsibleformostoftheobservedtoxicity.Inthisreview,wewillattempttoprovideanoverviewofthefieldanddiscusssomeoftheproblemsassociatedwithcytokine-basedimmuno-genetherapyandpotentialsolutions.Cellular&MolecularImmunology.2005;2(2):81-91.

简介：

简介：DearEditor,IamDr.KhayWeiPohfromDepartmentofOphthalmology,HospitalKualaLumpur,Malaysia.IwritetoshareacaseofdiffusechoroidalhaemangiomainachildwithSturgerWebersyndromewhoshowedresolutionofexudativeretinal

简介：无

简介：Wehavetreated120casesofacnewithscatteredneedlingtherapyataffectedpart.

简介：无

简介：在对待婴儿的肌肉发达的torticollis加超声的治疗观察tuina的临床的功效。

简介：

简介：Sincetheapprovalofrituximabin1997,monoclonalantibodies(mAbs)havebecomeanincreasinglyimportantcomponentoftherapeuticregimensinoncology.ThesuccessofmAbsasatherapeuticclassisaresultofgreatstridesthathavebeenmadeinmolecularbiologyandinbiotechnologyoverthepastseveraldecades.Currently,thereare14approvedmAbproductsforoncologyindications,andtherearetenadditionalmAbsinlatestagesofclinicaltrials.Comparedtotraditionalchemotherapeuticagents,mAbshaveseveraladvantages,includingalongcirculatinghalf-lifeandhightargetspecificity.Antibodiescanserveascytotoxicagentswhenadministeredalone,exertingapharmacologiceffectthroughseveralmechanismsinvolvingtheantigenbinding(Fab)and/orFcdomainsofthemolecule,andmAbsmayalsobeutilizedasdrugcarriers,targetingatoxicpayloadtocancercells.TheextremelyhighaffinityofmAbsfortheirtargets,whichisdesirablewithrespecttopharmacodynamics(i.e.,contributingtothehightherapeuticselectivityofmAb),oftenleadstocomplex,non-linear,target-mediatedpharmacokinetics.Inthisreport,wesummarizethepharmacokineticandpharmacodynamicsofmAbsthathavebeenapprovedandofmAbsthatarenearingapprovalforoncologyindications,withparticularfocusonthemolecularandcellularmechanismsresponsiblefortheirdispositionandefficacy.

简介：

简介：Toinvestigatetheeffectofphotodynamictherapy(PDT)withhematoporphrinmonomethylether(HMME)onbovineimmunodeficiencyvirus(BIV)canprovidethebasistheoryforphotoinactivationofhumanimmunodeficiencyvirus(HIV).ToassesstheprotectionofHMME-PDTonthecelllineCf2ThinfectedwithBIVR29by3-(4,5)-dimethylthiahiazol-2-yl-3,5-di-phenytetrazoliumbromide(MTT)withpowerdensityof5and25mW/cm~2andenergydensityfrom0.6to3J/cm~2.ToobservetheinhibitionofmembranefusionusinganewreportercelllineBIVEbyfluorescencemicroscope.HMME-PDThassignificantprotectanteffectsonCf2Th-BIVR29withbothpowerdensities,especiallyinthegroupofhighpowerdensity.FluorescentmicroscopeshowsthatthereisnosignificantdifferencebetweenthegroupofPDTandcontrol,whichmeansPDTcouldnotinhibittheBIV-mediatedmembranefusion.

简介：

简介：无

简介：Itiswellestablishedthatstemcellscandifferentiateintocelltypesoftheorganinwhichthesearetransplanted.However,theprocessisveryslowduetolackofunderstandingofsignalsimportantfortheirsurvivalanddifferentiation,mostoptimalstemcellsandtheirplasticity.Limitationsandadvantagesofvariouscellsubtypeswillbedescribed.Therateofstemcellsmobilizationandtheirsurvivalintheischemicenvironmentaremajorobstaclesinengraftmentanddifferentiationofstemcellsformeaningfulrepairoftheinfarctedmyocardium.Manipulationofstemcellswithischemicpreconditioning,combinedgeneandcelltherapytogetherwithsimultaneousactivationofdiversesignalingpathwaysformassivestemcellmobilization®enerationhassignificantimpactontherepairprocessbystemcells.Theseandotherdifficultiesencounteredinefficientuseofvariousstemcellshaveresultedininventionofinducedpluripotentstemcellswhichcouldrevolutionizethestemcellbasedtherapyandtheirapplicationsforunderstandingofhumandiseaseanddrugscreeninginthenearfuture.ReprogrammingofadultcellsintoiPScellswithouttheuseofviralvectorsisamajorchallengetowardsgettingiPScellswithoutviralintegrationintocells.Tomeetthischallengewehaverepro-grammedskeletalmyoblastsintoiPScellswithhighefficiencyusingepigeneticmodifiers.TransplantationofiPScellsderivedpurecardiacprogenitorsintoinfarctedmyocardiumledtoextensiverepopulationofscarareawithfullydevelopedmyocyteswithouttumorformationandresultinginmarkedimprovementincardiacfunction.Reprogrammingwithpurechemicalmeanswillmaketherapeuticuseofthesecellsmoresafer.Targetingtheinducedpluripotentstemcellstowardscardiacprogenitorsandtheirapplicationtowardstransplantationisamajorstepforwardinenhancingthemyocardialrepaircapacitybythesecells.

简介：

简介：在这份报纸，我们独自考察了雄激素剥夺治疗(ADT)的长期的幸存结果，安全，和quality-of-life对为局部地先进、变形的前列腺癌症(PCa)与放射治疗(RT)或化疗结合了。文学搜索用OvidSP被执行。满足了下列标准的使随机化的控制试用(RCT)被包括：包括局部地先进或变形的PCa，比较方法和疾病的报导量的数据控制的与任何治疗独自一个对联合的ADT或幸存结果。最后，八RCT满足了包括标准。在这些之中，三比较了ADT对ADT正RT(n=2344)并且一个人比较了ADT对ADT正docetaxel-estramustine(n=413)在局部地先进的PCa；二比较了ADT对ADT正docetaxel(n=1175)并且加estramustine的二比较ADT对ADT(n=114)在变形PCa。为局部地先进的PCa，到长期的ADT的RT的增加能与充分可接受的不利效果改进幸存和肿瘤控制的结果。特殊，分享的机会比率(或)外套，幸存(OS)是1.43(95%信心间隔1.20-1.71)什么时候独自加RT把ADT与ADT作比较(P<0.0001)。为变形神经质地敏感的PCa，加ADT的docetaxel的并发的使用有效、安全(分享或OS：1.29[1.01-1.65]：P=0.04)。总共，加docetaxel的长期的ADT正RT和长期的ADT应该分别地在局部地先进、变形的神经质地敏感的PCa被看作合适的处理选择。为纸的主要限制是仅仅八RCT是可得到的。